Journal for ImmunoTherapy of Cancer (Nov 2020)

357 TAK-573, an anti-CD38–attenuated interferon alpha (IFNα) fusion protein (Attenukine™), has demonstrated IFNα receptor (IFNAR) pathway modulation in patients with relapsed/refractory multiple myeloma

  • Cheryl Li,
  • Lei Shen,
  • Sabrina Collins,
  • Adarsh Joshi,
  • Subhasree Das,
  • Kaveri Suryanarayan,
  • Dean Bottino,
  • Michael Curley,
  • Dannie Wang,
  • Michael Abadier,
  • Ryan Larson,
  • Xavier Parot

DOI
https://doi.org/10.1136/jitc-2020-SITC2020.0357
Journal volume & issue
Vol. 8, no. Suppl 3

Abstract

Read online

No abstracts available.